181 related articles for article (PubMed ID: 25746813)
21. An orally bioavailable chemical probe of the Lysine Methyltransferases EZH2 and EZH1.
Konze KD; Ma A; Li F; Barsyte-Lovejoy D; Parton T; Macnevin CJ; Liu F; Gao C; Huang XP; Kuznetsova E; Rougie M; Jiang A; Pattenden SG; Norris JL; James LI; Roth BL; Brown PJ; Frye SV; Arrowsmith CH; Hahn KM; Wang GG; Vedadi M; Jin J
ACS Chem Biol; 2013; 8(6):1324-34. PubMed ID: 23614352
[TBL] [Abstract][Full Text] [Related]
22. Identification of novel EZH2 inhibitors through pharmacophore-based virtual screening and biological assays.
Wu Y; Hu J; Ding H; Chen L; Zhang Y; Liu R; Xu P; Du D; Lu W; Liu J; Liu Y; Liu YC; Lu J; Zhang J; Yao Z; Luo C
Bioorg Med Chem Lett; 2016 Aug; 26(15):3813-7. PubMed ID: 27289323
[TBL] [Abstract][Full Text] [Related]
23. De novo peptide design and experimental validation of histone methyltransferase inhibitors.
Smadbeck J; Peterson MB; Zee BM; Garapaty S; Mago A; Lee C; Giannis A; Trojer P; Garcia BA; Floudas CA
PLoS One; 2014; 9(2):e90095. PubMed ID: 24587223
[TBL] [Abstract][Full Text] [Related]
24. Astemizole arrests the proliferation of cancer cells by disrupting the EZH2-EED interaction of polycomb repressive complex 2.
Kong X; Chen L; Jiao L; Jiang X; Lian F; Lu J; Zhu K; Du D; Liu J; Ding H; Zhang N; Shen J; Zheng M; Chen K; Liu X; Jiang H; Luo C
J Med Chem; 2014 Nov; 57(22):9512-21. PubMed ID: 25369470
[TBL] [Abstract][Full Text] [Related]
25. Design, synthesis and activity evaluation of quinolinone derivatives as EZH2 inhibitors.
Cai J; You H; Qin X; Wang Y; Li W
Bioorg Med Chem Lett; 2024 Jun; 105():129726. PubMed ID: 38580135
[TBL] [Abstract][Full Text] [Related]
26. An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED.
Qi W; Zhao K; Gu J; Huang Y; Wang Y; Zhang H; Zhang M; Zhang J; Yu Z; Li L; Teng L; Chuai S; Zhang C; Zhao M; Chan H; Chen Z; Fang D; Fei Q; Feng L; Feng L; Gao Y; Ge H; Ge X; Li G; Lingel A; Lin Y; Liu Y; Luo F; Shi M; Wang L; Wang Z; Yu Y; Zeng J; Zeng C; Zhang L; Zhang Q; Zhou S; Oyang C; Atadja P; Li E
Nat Chem Biol; 2017 Apr; 13(4):381-388. PubMed ID: 28135235
[TBL] [Abstract][Full Text] [Related]
27. Diverse, Potent, and Efficacious Inhibitors That Target the EED Subunit of the Polycomb Repressive Complex 2 Methyltransferase.
Bagal SK; Gregson C; O' Donovan DH; Pike KG; Bloecher A; Barton P; Borodovsky A; Code E; Fillery SM; Hsu JH; Kawatkar SP; Li C; Longmire D; Nai Y; Nash SC; Pike A; Robinson J; Read JA; Rawlins PB; Shen M; Tang J; Wang P; Woods H; Williamson B
J Med Chem; 2021 Dec; 64(23):17146-17183. PubMed ID: 34807608
[TBL] [Abstract][Full Text] [Related]
28. Small molecule inhibitors of EZH2: the emerging translational landscape.
Keilhack H; Smith JJ
Epigenomics; 2015; 7(3):337-41. PubMed ID: 26077423
[No Abstract] [Full Text] [Related]
29. The Importance of Being Me: Magic Methyls, Methyltransferase Inhibitors, and the Discovery of Tazemetostat.
Kuntz KW; Campbell JE; Keilhack H; Pollock RM; Knutson SK; Porter-Scott M; Richon VM; Sneeringer CJ; Wigle TJ; Allain CJ; Majer CR; Moyer MP; Copeland RA; Chesworth R
J Med Chem; 2016 Feb; 59(4):1556-64. PubMed ID: 26769278
[TBL] [Abstract][Full Text] [Related]
30. Acquisition of a single EZH2 D1 domain mutation confers acquired resistance to EZH2-targeted inhibitors.
Baker T; Nerle S; Pritchard J; Zhao B; Rivera VM; Garner A; Gonzalvez F
Oncotarget; 2015 Oct; 6(32):32646-55. PubMed ID: 26360609
[TBL] [Abstract][Full Text] [Related]
31. Convergent evolution of chromatin modification by structurally distinct enzymes: comparative enzymology of histone H3 Lys²⁷ methylation by human polycomb repressive complex 2 and vSET.
Swalm BM; Hallenbeck KK; Majer CR; Jin L; Scott MP; Moyer MP; Copeland RA; Wigle TJ
Biochem J; 2013 Jul; 453(2):241-7. PubMed ID: 23679895
[TBL] [Abstract][Full Text] [Related]
32. Structural basis of histone H3K27 trimethylation by an active polycomb repressive complex 2.
Jiao L; Liu X
Science; 2015 Oct; 350(6258):aac4383. PubMed ID: 26472914
[TBL] [Abstract][Full Text] [Related]
33. Potential inhibitors of S-adenosylmethionine-dependent methyltransferases. 4. Further modifications of the amino and base portions of S-adenosyl-L-homocysteine.
Borchardt RT; Huber JA; Wu YS
J Med Chem; 1976 Sep; 19(9):1094-9. PubMed ID: 978673
[TBL] [Abstract][Full Text] [Related]
34. S-adenosylhomocysteine induces inflammation through NFkB: A possible role for EZH2 in endothelial cell activation.
Barroso M; Kao D; Blom HJ; Tavares de Almeida I; Castro R; Loscalzo J; Handy DE
Biochim Biophys Acta; 2016 Jan; 1862(1):82-92. PubMed ID: 26506125
[TBL] [Abstract][Full Text] [Related]
35. 5-Methoxyquinoline Derivatives as a New Class of EZH2 Inhibitors.
Xiang P; Jie H; Zhou Y; Yang B; Wang HJ; Hu J; Hu J; Yang SY; Zhao YL
Molecules; 2015 Apr; 20(5):7620-36. PubMed ID: 25923513
[TBL] [Abstract][Full Text] [Related]
36. The potential roles of EZH2 in regenerative medicine.
Chou RH; Chiu L; Yu YL; Shyu WC
Cell Transplant; 2015; 24(3):313-7. PubMed ID: 25647295
[TBL] [Abstract][Full Text] [Related]
37. The polycomb group protein enhancer of zeste 2 is a novel therapeutic target for cervical cancer.
Ding M; Zhang H; Li Z; Wang C; Chen J; Shi L; Xu D; Gao Y
Clin Exp Pharmacol Physiol; 2015 May; 42(5):458-64. PubMed ID: 25739318
[TBL] [Abstract][Full Text] [Related]
38. Design and synthesis of (E)-1,2-diphenylethene-based EZH2 inhibitors.
He H; Hu X; Teng F; Liu Z; Zhang Q; Feng Z; Feng Q; Yu L
Bioorg Med Chem Lett; 2020 Mar; 30(5):126957. PubMed ID: 31959420
[TBL] [Abstract][Full Text] [Related]
39. Targeting histone methyltransferase EZH2 as cancer treatment.
Kondo Y
J Biochem; 2014 Nov; 156(5):249-57. PubMed ID: 25179367
[TBL] [Abstract][Full Text] [Related]
40. Structural insights into binding of small molecule inhibitors to Enhancer of Zeste Homolog 2.
Kalinić M; Zloh M; Erić S
J Comput Aided Mol Des; 2014 Nov; 28(11):1109-28. PubMed ID: 25139678
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]